

Amyotrophic Lateral Sclerosis (ALS)

REFERENCES

- Aldrich TK. Nutritional factors in the pathogenesis and therapy of respiratory insufficiency in neuromuscular diseases. *Monaldi Arch Chest Dis*. 1993;48(4):327–330.
- Andreassen OA, Dedeoglu A, et al. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. *Neuroreport*. 2000;11(11):2491–2493.
- Andreassen OA, Dedeoglu A, et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. *Exp Neurol*. 2001b;168(2):419–424.
- Andreassen OA, Jenkins BG, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. *J Neurochem*. 2001a;77(2):383–390.
- Apostolski S, Marinkovic Z, et al. Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. *J Environ Pathol Toxicol Oncol*. 1998;17(3–4):325–329.
- Ascherio AJ, Weisskopf MG, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. *Ann Neurol*. 2005;57(1):104–110.
- Banci L, Felli IC, et al. Direct detection of hydrogen bonds in monomeric superoxide dismutase: biological implications. *Biochemistry*. 2002;41(9):2913–2920.
- Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. *Free Radic Res*. 2002;36(4):455–460.
- Caban-Holt A, Mattingly M, et al. Neurodegenerative memory disorders: a potential role of environmental toxins. *Neurol Clin*. 2005;23(2):485–521.
- Cameron A, Rosenfeld J. Nutritional issues and supplements in amyotrophic lateral sclerosis and other neurodegenerative disorders. *Curr Opin Clin Nutr Metab Care*. 2002;5(6):631–643.
- Carta A, Calvani M, et al. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. *Ann N Y Acad Sci*. 1993;695:324–326.
- Cleveland DW. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. *Neuron*. 1999;24(3):515–520.
- Cuajungco MP, Lees GJ. Zinc metabolism in the brain: relevance to human neurodegenerative disorders. *Neurobiol Dis*. 1997;4(3–4):137–169.
- Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. *Pharmacol Ther*. 1999;81(3):163–221.
- Ermilova IP, Ermilov VB, et al. Protection by dietary zinc in ALS mutant G93A SOD transgenic mice. *Neurosci Lett*. 2005;379(1):42–46.
- Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. *Ann Intern Med*. 2002;136(1):42–53.
- Exner R, Wessner B, et al. Therapeutic potential of glutathione. *Wien Klin Wochenschr*. 2000;112(14):610–616.
- Ferrante RJ, Klein AM, et al. Therapeutic efficacy of EGb761 (*Ginkgo biloba* extract) in a transgenic mouse model of amyotrophic lateral sclerosis. *J Mol Neurosci*. 2001;17(1):89–96.
- Fosslien E. Mitochondrial medicine—molecular pathology of defective oxidative phosphorylation. *Ann Clin Lab Sci*. 2001;31(1):25–67.

- Graf M, Ecker D, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. *J Neural Transm* . 2005;112(5):649–660.
- Gresham LS, Molgaard CA , et al. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. *Neuroepidemiology* . 1986;5(1):29–38 .
- Hagen TM, Liu J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. *Proc Natl Acad Sci U S A*. 2002;99(4):1870–1875.
- Henderson JT, Javaheri M, et al. Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. *J Neurosci*. 1996;16(23):7574–7582.
- Hong JT, Ryu SR, et al. Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury. *Brain Res Bull*. 2000;53(6):743–749.
- Hu M, Skibsted LH. Kinetics of reduction of ferrylmyoglobin by (-)-epigallocatechin gallate and green tea extract. *J Agric Food Chem*. 2002;50(10):2998–3003.
- Jiang F, DeSilva S, et al. Beneficial effect of ginseng root in SOD-1 (G93A) transgenic mice. *J Neurol Sci* . 2000;180(1–2):52–54.
- Kaji R, Kodama M, et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. *Muscle Nerve* . 1998;21(12):1775–1778.
- Kimionides VG, Khatibi NH , et al. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. *Proc Natl Acad Sci U S A*. 1998;95(4):1852–1857.
- Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. *Free Radic Res*. 2000;32(2):115–124.
- Lacomblez L, Bensimon G, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. *Neurology*. 1996;47(6 Suppl 4):S242–S250.
- Lapchak PA, Araujo DM. Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases. *Int Rev Neurobiol*. 2001;46:379–397.
- Levites Y, Youdim MB , et al. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. *Biochem Pharmacol*. 2002;63(1):21–29.
- Li HF, Chen SA, et al. Evidence for the stimulatory effect of resveratrol on Ca(2+)- activated K+ current in vascular endothelial cells. *Cardiovasc Res* . 2000;45(4):1035–1045.
- Li J, Lin-Shia S. Mechanisms of cancer chemoprevention by curcumin. *Proceedings of the National Science Council, Republic of China —Part B, Life Sciences*. 2001;25:59–66.
- Lim GP, Chu T, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *J Neurosci*. 2001;21(21):8370–8377.
- Logan-Smith MJ, Lockyer PJ, et al. Curcumin, a molecule that inhibits the Ca²⁺-ATPase of sarcoplasmic reticulum but increases the rate of accumulation of Ca²⁺. *J Biol Chem*. 2001;276(50):46905–46911.
- Louwerse ES, Weverling GJ, et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. *Arch Neurol*. 1995;52(6):559–564.
- Mano Y, Takayanagi T, et al. [Amyotrophic lateral sclerosis and mercury—preliminary report]. *Rinsho Shinkeigaku* . 1990;30(11):1275–1277.
- Mao X, Barger SW. Neuroprotection by dehydroepiandrosterone-sulfate: role of an NFkappaB-like factor. *Neuroreport*. 1998;9(4):759–763.

Martin D, Thompson MA, et al. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. *Eur J Pharmacol.* 1993;250(3):473–476.

Matthews RT, Yang L, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. *Proc Natl Acad Sci U S A.* 1998;95(15):8892–8897.

Mazzini L, Balzarini C, et al. Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. *J Neurol Sci.* 2001;191(1–2):139–144.

Menzies FM, Ince PG, et al. Mitochondrial involvement in amyotrophic lateral sclerosis. *Neurochem Int.* 2002;40(6):543–551.

Mitchell J. Amyotrophic lateral sclerosis: toxins and environment. *Amyotroph Lateral Scler Other Motor Neuron Disord.* 2000;1(4):235–250.

Muller U, Kriegelstein J. Prolonged pretreatment with alpha-lipoic acid protects cultured neurons against hypoxic, glutamate-, or iron-induced injury. *J Cereb Blood Flow Metab.* 1995;15(4):624–630.

Murray R, Granner D, et al. *Harper's Biochemistry.* Vol. 25. Los Altos, Calif.: Lange Medical Publications, Appleton and Lange; 1999

Naidu KA, Thippeswamy NB. Inhibition of human low density lipoprotein oxidation by active principles from spices. *Mol Cell Biochem.* 2002;229(1–2):19–23.

Packer L, Rimbach G, et al. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (*Pinus maritima*) bark, pycnogenol. *Free Radic Biol Med.* 1999;27(5–6):704–724.

Palma A, de Carvalho M, et al. Biochemical characterization of plasma in amyotrophic lateral sclerosis: amino acid and protein composition. *Amyotroph Lateral Scler Other Motor Neuron Disord.* 2005;6(2):104–110.

Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. *Pharmacol Rev.* 2001;53(2):161–176.

Pioro EP. Antioxidant therapy in ALS. *Amyotroph Lateral Scler Other Motor Neuron Disord.* 2000;1(Suppl 4):5–12; discussion 13–15.

Rosen DR, Siddique T, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature.* 1993;362(6415):59–62.

Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. *Adv Neurol.* 1995;68:7–20; discussion 21–27.

Rowland L. Amyotrophic lateral sclerosis: theories and therapies. *J Neurol Sci.* 1994;31(169):126–127.

Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. *N Engl J Med.* 2001;344(22):1688–1700.

Salini V, Cova L, et al. Stem-cell therapy for amyotrophic lateral sclerosis. *Lancet.* 2004;364(9429):200–202.

Sohmiya M, Tanaka M, et al. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. *J Neurol Sci.* 2005;228(1):49–53.

Sumbilla C, Lewis D, et al. The slippage of the Ca²⁺ pump and its control by anions and curcumin in skeletal and cardiac sarcoplasmic reticulum. *J Biol Chem.* 2002;277(16):13900–13906.

Sung JJ, Kim HJ, et al. Homocysteine induces oxidative cytotoxicity in Cu, Zn-superoxide dismutase mutant motor neuronal cell. *Neuroreport.* 2002;13(4):377–381.

Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. *Ann Neurol.* 2001;49(5):561–574.

Thal LJ, Calvani M, et al. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. *Neurology.* 2000;55(6):805–810.

Vielhaber S, Kaufmann J, et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. *Exp Neurol*. 2001;172(2):377–382.

Wu SN. Large-conductance Ca²⁺- activated K⁺ channels: physiological role and pharmacology. *Curr Med Chem* . 2003;10(8):649–661.

Wu SN, Li HF, et al. Vinpocetine-enhanced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. *Biochem Pharmacol* . 2001;61(7):877–892.

Zhang WJ, Frei B. Alpha lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. *Faseb J* . 2001;15(13): 2423–2432.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension[®]

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.